APA (7th ed.) Citation

A, C., S, D., FA, H., B, M., H, I., VJ, H., . . . M, M. (2016). Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 17(3), 367. https://doi.org/10.1016/S1470-2045(15)00551-3

Chicago Style (17th ed.) Citation

A, Chan, et al. "Neratinib After Trastuzumab-based Adjuvant Therapy in Patients with HER2-positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 17, no. 3 (2016): 367. https://doi.org/10.1016/S1470-2045(15)00551-3.

MLA (9th ed.) Citation

A, Chan, et al. "Neratinib After Trastuzumab-based Adjuvant Therapy in Patients with HER2-positive Breast Cancer (ExteNET): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 17, no. 3, 2016, p. 367, https://doi.org/10.1016/S1470-2045(15)00551-3.